a method of reducing pulmonary arterial hypertension in a mammal that employs fk506 is provided . in certain embodiments , the method comprises administering fk506 to a mammal having pulmonary arterial hypertension associated with defective mbpr2 signaling at a dosage sufficient to reduce blood pressure in the pulmonary artery of the mammal .